Michel M Sun
Overview
Explore the profile of Michel M Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang C, Chu A, Meyer S, Ding Y, Sun M, Abiri P, et al.
Theranostics
. 2021 Jan;
11(3):1162-1175.
PMID: 33391527
Murine models provide microvascular insights into the 3-D network disarray seen in retinopathy and cardiovascular diseases. Light-sheet fluorescence microscopy (LSFM) has emerged to capture retinal vasculature in 3-D, allowing for...
2.
Braun D, Getahun D, Chiu V, Coleman A, Holland G, Yu F, et al.
Am J Ophthalmol
. 2020 Dec;
224:282-291.
PMID: 33359682
Purpose: To examine the frequency of ophthalmic immune-related adverse events (OirAEs) in melanoma, other cancers, and after immune checkpoint inhibitor (ICI) treatment. Design: Retrospective clinical cohort study. Methods: This study...
3.
Sun M, Kelly S, Mylavarapu Bs A, Holland G, Coleman A, Yu F, et al.
Ophthalmology
. 2020 Nov;
128(6):910-919.
PMID: 33166553
Purpose: Detailed study of ophthalmic immune-related adverse events (AEs), including determination of incidence and recurrence rates, is of integral importance in cancer immunotherapy to inform management and treatment guidelines. Design:...
4.
Sun M, Seleme N, Chen J, Zekeridou A, Sechi E, Walsh R, et al.
J Neuroophthalmol
. 2020 Nov;
41(4):519-530.
PMID: 33136674
Background: In recent years, CTLA-4 and PD-1/PD-L1 checkpoint inhibitors have proven to be effective and have become increasingly popular treatment options for metastatic melanoma and other cancers. These agents work...
5.
Patel K, Kejriwal S, Sun M, Thammachantha S, Duong C, Chan A, et al.
J Neurooncol
. 2020 Jan;
147(1):15-24.
PMID: 31981014
Purpose: Although intracranial meningiomas are the most common primary brain tumor in adults, treatment options are few and have traditionally been limited to surgical resection and radiotherapy. Additional targeted therapies...
6.
Sun M, Gordon L, Levinson R
JAMA Ophthalmol
. 2019 Mar;
137(5):583-584.
PMID: 30869756
No abstract available.
7.
Sun M, Chan A, Law S, Duarte S, Diaz-Aguilar D, Wadehra M, et al.
Invest Ophthalmol Vis Sci
. 2019 Jan;
60(1):245-254.
PMID: 30646013
Purpose: Pathologic corneal neovascularization is a major cause of blindness worldwide, and treatment options are currently limited. VEGF is one of the critical mediators of corneal neovascularization but current anti-VEGF...
8.
Fogel L, Sun M, Geurs T, Carayannopoulos L, French A
J Immunol
. 2013 May;
190(12):6269-76.
PMID: 23656738
NK cell activation is controlled by the integration of signals from cytokine receptors and germline-encoded activation and inhibitory receptors. NK cells undergo two distinct phases of activation during murine CMV...